Exhibition Information
Menu
Exhibition Opening Hours
- Friday 23rd May - 14:00 - 19:00
- Saturday 24th May - 09:00 - 18:00
- Sunday 25th May - 09:00 - 12:30
Exhibiting Companies
GVBM is a German distribution company founded in 2013 and specializing in disposables for surgery. Notable fields of expertise are keratoplasty and lacrimal duct procedures, both of which GVBM offers a wide range of products, although its portfolio is not limited to these areas.
Heidelberg Engineering pioneers imaging and data technologies to optimize ophthalmic solutions and support learning that advances research and empowers clinicians who want to improve the holistic health of patients. From its inception in 1990, the Company has collaborated with scientists, clinicians and industry to develop innovative products that deliver clinically relevant benefits.
Uncompromising quality and education play a large part in fostering the diagnostic confidence that has become synonymous with the global brand. The Company’s substantial expertise in the development and implementation of intelligent image and data management solutions complements its distinguished history in the design, manufacture and distribution of ophthalmic diagnostic instruments.
Heidelberg Engineering’s growing product portfolio combines these core technologies: confocal microscopy, scanning lasers and optics, optical coherence tomography (OCT), real-time image processing and analytics, multimodal image management solutions (PACS), electronic medical records (EMR) and large-scale data analysis.
The company’s ophthalmic diagnostic solutions and technologies are empowering clinicians to improve patient care in 120 countries, via 54 distributors.
Heidelberg Engineering GmbH
Max Jarecki Str. 8
69115 Heidelberg GERMANY
Phone: +49 6221 6463 0
Web: www.HeidelbergEngineering.com
Founded in 2003, Horus Pharma is an independent French pharmaceutical Laboratory specialized in ophthalmology which is part of the French and European landscape.
Since the creation of the Laboratory, Horus Pharma has been a pioneer in the development of preservative-free formulations and products and has extended its expertise to dermatology and cosmetics.
Laboratoires KÔL was established in February 2020 to provide solutions to unmet needs in the field of ophthalmology, with a particular focus on corneal treatments and rare diseases.
A vocation to provide best in class pharmaceutical solutions to uncovered needs in the corneal field. An agile mindset to fast-track whenever possible product access for the benefit of patients. A team with a strong expertise in ophthalmic product development where every voice counts, listening to patients and doctors.
Our DNA :
KÔL is thus a new generation of pharmaceutical company : We are a French startup, at the heart of a dynamic entrepreneurial network in Clermont-Ferrand: one of the cradles of ophthalmology in France. We have an international ambition, and are proud and keen to export our French know-how.
Providing quality products that showcase French industrial expertise In-house expertise in the development of ophthalmic products. Partnering with selected public and/or private partners to boost our developments, create relevant synergies and increase our international footprint.
Innovative Products : Laboratoires KÔL currently markets two pharmaceutical products in eye drop solutions with Compassionate Access Authorisation. These derogatory authorisations are designed to make products available to patients to treat rare and serious diseases for which there is no therapeutic alternative.
MEDIPHACOS is a world-class company with over 50 years of experience in ophthalmology and presence in more than 60 countries in 5 continents. Our mission is to restore, preserve and improve human vision in collaboration with ophthalmologists through innovative, safe and effective products and services, like KERARING. KERARING are surgically implantable devices used to reduce corneal topographic irregularities, correct low and high-order optical aberrations and improve visual acuity in patients with keratoconus and other ectatic disorders. KERARING was specifically designed to treat irregular corneas and has been the treatment choice for hundreds of thousands of patients globally for over 20 years with excellent safety, efficacy and low complication rates.
Email: info.europe@mediphacos.com
URL: www.mediphacos.com
Since 1895 OCULUS has been a trusted partner for eye care professionals around the world. With the highest attention to detail, our devices are designed and manufactured at the OCULUS headquarters in Germany.
Stop by our booth to find out why it is clever to integrate the new Pentacam® Cornea OCT to your practice. Test the latest OCULUS device and talk to our product specialists – we are here for you.
SIFI, leading ophthalmic company, headquartered in Italy, since 1935 develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic disorders. SIFI portfolio includes innovative pharmaceuticals, medical devices and food supplements exported to more than 60 countries worldwide.
SIFI has direct commercial operations in Italy, France, Spain, Romania, Turkey and Mexico.
In 2022 SIFI has entered into an agreement to establish a Joint Venture to develop, manufacture and commercialize premium innovative intraocular lenses (“IOLs”) in the Greater China market, including Taiwan, Macau and Hong Kong and the United Arab Emirates in 2024.
In October 2024, Akantior, the new drug for Acanthamoeba Keratitis ultra-rare corneal disease, has been launched in Germany. It’s going to be launched in Italy and in US.
Akantior is also going through the regulatory approval procedures for fungal keratitis.
Théa is a profoundly European company whose independence, stability and entrepreneurial spirit are safeguarded by the Chibret family, which has been instrumental in the field of ophthalmology for over 150 years. Being a family-owned business has allowed Théa to develop over the long-term, focusing on employees and human values to fulfil our mission of being ‘The’ ophthalmology specialist. A pioneer in preservative-free treatments, we are committed to providing healthcare professionals and patients with innovative products and a wide range of specialty items (service products, daily-use products) across all ophthalmological therapeutic classes.
We are continually reinvesting in our two main areas of interest, Innovation and Internationalisation, with long-term strategy being favoured over immediate profit. Our goal is to pursue and strengthen lasting partnerships and collaborative research, to share our expertise and address unmet medical needs to provide new methods for treating and supporting patients. Internationalisation is in our genes: currently the leading independent eye care group in Europe, Théa has set its sights on becoming a world leader by continuing to export its products and establish itself internationally, while always respecting the cultures of each country.